Adamis tries to make its mark with low-cost epinephrine injector
- Adamis has filed a new drug application for Epinephrine Injection, USP, 1:1000 -- a 0.3 mg pre-filled single-dose syringe (PFS) intended for the emergency treatment of allergic reactions -- that will be reviewed by the FDA.
- Adamis focuses on delivering specialty products at lower price points.
- Adamis is aiming for respiratory approval during the first half of 2015.
Adamis Pharmaceuticals is going after a market that is estimated to be worth approximately $900 million. During the development and design stage, Adamis took steps to create a low-cost alternative to the leading epinephrine auto-injectors. Adamis is also developing therapies for the treatment of asthma and COPD.
Prescribing epinephrine as an anaphylaxis treatment has become increasingly common, according to the Wall Street Journal, presenting Adamis an opportunity to make its mark in a market that is only likely to grow.
- Pharmaceutical Business Review FDA accepts to review Adamis' NDA for Epinephrine pre-filled syringe